Screening EPA list N quaternary ammonium compounds for enhanced bactericidal activity in all-purpose cleaners
A microbiology screening service to identify optimal quaternary ammonium compounds from the EPA List N for incorporation into all-purpose cleaners. The project aims to achieve 3 to 5 log reductions in bacterial counts at low concentrations (100 to 1000 ppm) over 2 to 5 days, with optional salt additives to boost efficacy.
Overview
This offering provides a targeted screening and optimization service for identifying the most effective quaternary ammonium compounds from the EPA List N for use in all-purpose cleaners. Quaternary ammonium compounds are well-known disinfectants, but this service focuses on finding formulations that deliver strong bactericidal performance at relatively low concentrations (100 to 1000 ppm) over extended contact periods of 2 to 5 days. The approach combines compound screening with salt additive optimization to enhance bacterial kill rates, offering a practical solution for cleaning product manufacturers seeking EPA-recognized active ingredients.
Technical specifications
Key capabilities:
- Screening of EPA List N quaternary ammonium compounds for bactericidal activity at 100 to 1000 ppm concentrations in an all-purpose cleaner matrix
- Microbiological characterization using established laboratory methods to quantify log reductions in bacterial counts
- Evaluation of contact times ranging from 2 to 5 days to identify compounds with sustained efficacy
- Optimization through salt addition (e.g., sodium chloride) at varying concentrations to impede bacterial metabolism and enhance kill rates
- Testing against pathogens of interest once the optimal compound and salt combination is identified
Prior experience:
- Previous screening of quaternary ammonium compounds for development purposes with observed 3 to 5 log reductions at higher concentrations (10,000 to 100,000 ppm) within 30 minutes
- Existing microbiology facilities equipped for bactericidal characterization and screening
Technology readiness level
This service is at an early-to-mid stage development level. The provider has demonstrated proof-of-concept through prior screening work at higher concentrations, confirming the bactericidal potential of quaternary ammonium compounds. The proposed work extends these findings to lower, more commercially relevant concentrations and longer contact times. Validation steps include procurement of EPA List N compounds, systematic screening, identification of the highest-efficacy compound, and salt optimization. Final validation will characterize the bactericidal effect across all target pathogens once the optimal formulation is established.
About Spectral Platforms
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.
delivered to your inbox.